710 / 1068
Conclusion
•
Cape/5-FU based CRT remains standard
•
Oxaliplatin + CRT: more tox, less compliance
•
But: DFS improved even if only added to CRT (!?!)
•
CAPOX/FOLFOX as induction-/consolidation Tx (?)
•
EGFR-/VEGF-Inhibition: no phase III data
•
Other pathways: early phase I/II